Market Overview

Xeris Pharmaceuticals: Q1 Earnings Insights


Shares of Xeris Pharmaceuticals (NASDAQ:XERS) gained 11% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 16.82% year over year to ($0.89), which were in line with the estimate of ($0.89).

Revenue of $1,788,000 rose by 620.97% year over year, which beat the estimate of $1,430,000.


Xeris Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Price Action

52-week high: $12.98

52-week low: $1.42

Price action over last quarter: Up 48.60%

Company Description

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.


Related Articles (XERS)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at